Compare ITGR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITGR | TRVI |
|---|---|---|
| Founded | 1970 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2000 | 2019 |
| Metric | ITGR | TRVI |
|---|---|---|
| Price | $98.42 | $17.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $91.14 | $21.55 |
| AVG Volume (30 Days) | 432.0K | ★ 3.0M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $1,853,637,000.00 | N/A |
| Revenue This Year | $1.69 | N/A |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | $203.13 | ★ N/A |
| Revenue Growth | ★ 7.98 | N/A |
| 52 Week Low | $62.00 | $6.55 |
| 52 Week High | $111.99 | $20.22 |
| Indicator | ITGR | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 50.62 |
| Support Level | $88.32 | $10.07 |
| Resistance Level | $99.89 | $20.19 |
| Average True Range (ATR) | 2.78 | 1.40 |
| MACD | 0.23 | -0.23 |
| Stochastic Oscillator | 83.06 | 27.89 |
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.